New 'Off-the-Shelf' cell therapy trial offers hope for kids with tough leukemia

NCT ID NCT04881240

Summary

This is a first-in-human study to test the safety and find the right dose of a new type of CAR T-cell therapy for children and young adults (up to age 21) whose CD19-positive leukemia has come back or hasn't responded to other treatments. The therapy uses immune cells (T-cells) from a healthy donor, which are engineered in a lab to target and fight the leukemia. The main goals are to see how safe the treatment is and to learn if it can help control the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • St. Jude Children's Research Hospital

    RECRUITING

    Memphis, Tennessee, 38105, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.